[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A (experimental)- 60 participantspatients will receive Firazyr\u00ae (Icatibant acetate 30 mg); a subcutaneous injection in the abdominal area administered at intervals of 8 hours for 4 days; plus standard care to Cover-19. Group B (experimental)- 60 participants patients will receive Berinert\u00ae [plasma-derived C1 Esterase Inhibitor (Human)]; that will be administered at a dose of 20 IU per kg body weight on day 1 and on day 4; plus standard care. Group C (active control)- 60 participants patients will receive standard care to Covid-19 alone. The standard care will provide always use of antibiotics intravenously and use of prophylactic antithrombotic therapy. The oxygen support; noninvasive and invasive mechanical ventilation; use of vasopressor and renal support therapy will also be provided in the standard care; but those will be according to medical judgment.;Drug;D27.505.519.265.500;D12.776.124.486.274.920", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 601, "treatment_name": "Human plasma-derived c1 esterase inhibitor", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 621, "treatment_name": "Icatibant", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]